Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0117042
DC FieldValue
dc.titleAlphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 protein antigen
dc.contributor.authorKnudsen M.L.
dc.contributor.authorLjungberg K.
dc.contributor.authorTatoud R.
dc.contributor.authorWeber J.
dc.contributor.authorEsteban M.
dc.contributor.authorLiljeström P.
dc.date.accessioned2019-11-07T05:03:08Z
dc.date.available2019-11-07T05:03:08Z
dc.date.issued2015
dc.identifier.citationKnudsen M.L., Ljungberg K., Tatoud R., Weber J., Esteban M., Liljeström P. (2015). Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant Modified Vaccinia Ankara (MVA) or with HIV gp140 protein antigen. PLoS ONE 10 (2) : e0117042. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0117042
dc.identifier.issn19326203
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/161750
dc.description.abstractVaccination with DNA is an attractive strategy for induction of pathogen-specific T cells and antibodies. Studies in humans have shown that DNA vaccines are safe, but their immunogenicity needs further improvement. As a step towards this goal, we have previously demonstrated that immunogenicity is increased with the use of an alphavirus DNA-launched replicon (DREP) vector compared to conventional DNA vaccines. In this study, we investigated the effect of varying the dose and number of administrations of DREP when given as a prime prior to a heterologous boost with poxvirus vector (MVA) and/or HIV gp140 protein formulated in glucopyranosyl lipid A (GLA-AF) adjuvant. The DREP and MVA vaccine constructs encoded Env and a Gag-Pol-Nef fusion protein from HIV clade C. One to three administrations of 0.2 μg DREP induced lower HIV-specific T cell and IgG responses than the equivalent number of immunizations with 10 μg DREP. However, the two doses were equally efficient as a priming component in a heterologous prime-boost regimen. The magnitude of immune responses depended on the number of priming immunizations rather than the dose. A single low dose of DREP prior to a heterologous boost resulted in greatly increased immune responses compared to MVA or protein antigen alone, demonstrating that a mere 0.2 μg DREP was sufficient for priming immune responses. Following a DREP prime, T cell responses were expanded greatly by an MVA boost, and IgG responses were also expanded when boosted with protein antigen. When MVA and protein were administered simultaneously following multiple DREP primes, responses were slightly compromised compared to administering them sequentially. In conclusion, we have demonstrated efficient priming of HIV-specific T cell and IgG responses with a low dose of DREP, and shown that the priming effect depends on number of primes administered rather than dose. © 2015 Knudsen et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20191101
dc.subjectglycoprotein gp 140
dc.subjectHuman immunodeficiency virus antigen
dc.subjectHuman immunodeficiency virus vaccine
dc.subjecthybrid protein
dc.subjectimmunoglobulin G
dc.subjectmodified vaccinia virus Ankara vaccine
dc.subjectpoxvirus vector
dc.subjectunclassified drug
dc.subjectvaccinia vaccine
dc.subjectvirus DNA
dc.subjectDNA vaccine
dc.subjectgp140 envelope protein, Human immunodeficiency virus 1
dc.subjectHuman immunodeficiency virus antigen
dc.subjectimmunoglobulin G
dc.subjectlipid A
dc.subjectrecombinant DNA
dc.subjectvirus antibody
dc.subjectvirus DNA
dc.subjectvirus envelope protein
dc.subjectAlpha virus
dc.subjectanimal cell
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectantigen expression
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectdrug formulation
dc.subjectfemale
dc.subjectgene sequence
dc.subjectgenetic code
dc.subjectHuman immunodeficiency virus infection
dc.subjectimmune response
dc.subjectimmunization
dc.subjectin vivo study
dc.subjectmouse
dc.subjectnonhuman
dc.subjectT lymphocyte
dc.subjectAlphavirus
dc.subjectanimal
dc.subjectBagg albino mouse
dc.subjectchemistry
dc.subjectgene expression
dc.subjectgene vector
dc.subjectgenetics
dc.subjectHuman immunodeficiency virus 1
dc.subjectimmunization
dc.subjectimmunology
dc.subjectmedicinal chemistry
dc.subjectreplicon
dc.subjectVaccinia virus
dc.subjectAlphavirus
dc.subjectPoxviridae
dc.subjectAlphavirus
dc.subjectAnimals
dc.subjectAntibodies, Viral
dc.subjectChemistry, Pharmaceutical
dc.subjectDNA, Recombinant
dc.subjectDNA, Viral
dc.subjectenv Gene Products, Human Immunodeficiency Virus
dc.subjectFemale
dc.subjectGene Expression
dc.subjectGenetic Vectors
dc.subjectHIV Antigens
dc.subjectHIV-1
dc.subjectImmunization, Secondary
dc.subjectImmunoglobulin G
dc.subjectLipid A
dc.subjectMice
dc.subjectMice, Inbred BALB C
dc.subjectReplicon
dc.subjectT-Lymphocytes
dc.subjectVaccines, DNA
dc.subjectVaccinia virus
dc.typeArticle
dc.contributor.departmentMICROBIOLOGY AND IMMUNOLOGY
dc.description.doi10.1371/journal.pone.0117042
dc.description.sourcetitlePLoS ONE
dc.description.volume10
dc.description.issue2
dc.description.pagee0117042
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0117042.pdf742.28 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons